As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...

PhaseV, a leader in AI/ML for clinical development, today announced the launch of its AI Conductor, a centralized platform ...

The U.S. Food and Drug Administration (FDA) published the draft guidance “Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices,” which provides advice for ...

HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in ...

Calgary, Alberta –TheNewswire -May 22, 2025- Ocumetics Technology Corp (OTCFF). (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the submissionof its first-in-human (FIH ...

The newly introduced AI-powered study build engine marks the first phase of ClinCapture's broader intelligent trial roadmap. By automating protocol translation, Captivate establishes a foundation for ...

MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based ...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...

Background The length of hospital stay for patients with physical illnesses is longer for those with mental health comorbidity, particularly in the presence of severe physical multimorbidity.

MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc (BRTX). (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a ...